Filing Details

Accession Number:
0001827672-23-000018
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-17 18:02:30
Reporting Period:
2023-03-15
Accepted Time:
2023-03-17 18:02:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1819790 Tarsus Pharmaceuticals Inc. TARS Biological Products, (No Disgnostic Substances) (2836) 814717861
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1827672 R. Bobak Azamian C/O Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road, Suite 160
Irvine CA 92618
President/Ceo And Board Chair Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-03-15 8,000 $13.79 1,080,536 No 4 S Indirect By the Bobak Azamian Living Trust established April 16, 2018
Common Stock Acquisiton 2023-03-15 11,299 $0.00 13,049 No 4 M Direct
Common Stock Disposition 2023-03-16 791 $13.43 12,258 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By the Bobak Azamian Living Trust established April 16, 2018
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-03-15 11,299 $0.00 11,299 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
33,898 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.
  2. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.52 to $14.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
  4. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
  5. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholdingobligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  6. Each RSU represents a contingent right to receive one share of the Company's common stock.
  7. RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service.